
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMG-1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Designs for Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Designs for Health Launches Progenalen® Pro Peptide for Metabolic Health and Aging
Details : IMG-1, an unconjugated peptide, shows promise in promoting healthy blood sugar metabolism.
Product Name : Progenalen Pro Peptide
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 27, 2025
Lead Product(s) : IMG-1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Designs for Health
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMG-1
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : IP Investors LLC
Deal Size : $32.5 million
Deal Type : Series A Financing
Details : The net proceeds will be used to advance the company's priority programs in regenerative medicine, oral delivery, and therapeutics and for the continued development of its novel IMG-1 polypeptide.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 31, 2023
Lead Product(s) : IMG-1
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : IP Investors LLC
Deal Size : $32.5 million
Deal Type : Series A Financing

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : Lygenesis
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The research collaboration will leverage Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Lygenesis
Deal Size : Undisclosed
Deal Type : Collaboration
